Anesthetic Effect – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Anesthetic Effect – Pipeline Review, H2 2019’, provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect

– The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects

– The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Anesthetic Effect”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Andros Pharmaceuticals Co Ltd

Crescita Therapeutics Inc

Cuda Pharmaceuticals LLC

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Grunenthal GmbH

Hangzhou Adamerck Pharmlabs Inc

Hefei Cosource Pharmaceutical Inc

Jiangsu Hengrui Medicine Co Ltd

Lannett Co Inc

Lee’s Pharmaceutical Holdings Ltd

LipoSeuticals Inc

MedinCell SA

NutriBand Inc

Paion AG

Phosphagenics Ltd

Physica Pharma

Recro Pharma Inc

Sichuan Haisco Pharmaceutical Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

SiteOne Therapeutics Inc

Sphaera Pharma Pte Ltd

Yichang Humanwell Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anesthetic Effect Overview

Anesthetic Effect Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anesthetic Effect Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anesthetic Effect Companies Involved in Therapeutics Development

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Grunenthal GmbH

Lannett Company Inc

Lee's Pharmaceutical Holdings Ltd

MedinCell SA

Paion AG

Phosphagenics Ltd

Physica Pharma

Recro Pharma Inc

Sichuan Kelun Pharmaceutical Co Ltd

SiteOne Therapeutics Inc

Sphaera Pharma Pte Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Anesthetic Effect Drug Profiles

(bupivacaine + neosaxitoxin) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(lidocaine + prilocaine) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alphaxalone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0498 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0765 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cocaine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-09 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Flexicaine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fospropofol disodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSK-3486 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-100137 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDC-CMV Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHY-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2000 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block NaV1.7 for Local Anesthetic Effect Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NMDA Receptor for Anesthesia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-819 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anesthetic Effect Dormant Projects

Anesthetic Effect Discontinued Products

Anesthetic Effect Product Development Milestones

Featured News & Press Releases

Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea

Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia

Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting

Mar 20, 2018: Phosphagenics/Terumo R&D alliance to focus on TPM Injectables: TPM/Oxymorphone Patch Development to move outside Agreement

Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Korea

Nov 09, 2017: Phosphagenics Provides Update on TPM/Propofol Development Program

Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU

Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial

Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Table 1: Number of Products under Development for Anesthetic Effect, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 6: Products under Development by Universities/Institutes, H2 2019

Table 7: Number of Products by Stage and Target, H2 2019

Table 8: Number of Products by Stage and Mechanism of Action, H2 2019

Table 9: Number of Products by Stage and Route of Administration, H2 2019

Table 10: Number of Products by Stage and Molecule Type, H2 2019

Table 11: Anesthetic Effect – Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019

Table 12: Anesthetic Effect – Pipeline by Crescita Therapeutics Inc, H2 2019

Table 13: Anesthetic Effect – Pipeline by Cuda Pharmaceuticals LLC, H2 2019

Table 14: Anesthetic Effect – Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2019

Table 15: Anesthetic Effect – Pipeline by Expanesthetics Inc, H2 2019

Table 16: Anesthetic Effect – Pipeline by Grunenthal GmbH, H2 2019

Table 17: Anesthetic Effect – Pipeline by Hangzhou Adamerck Pharmlabs Inc, H2 2019

Table 18: Anesthetic Effect – Pipeline by Hefei Cosource Pharmaceutical Inc, H2 2019

Table 19: Anesthetic Effect – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Table 20: Anesthetic Effect – Pipeline by Lannett Co Inc, H2 2019

Table 21: Anesthetic Effect – Pipeline by Lee’s Pharmaceutical Holdings Ltd, H2 2019

Table 22: Anesthetic Effect – Pipeline by LipoSeuticals Inc, H2 2019

Table 23: Anesthetic Effect – Pipeline by MedinCell SA, H2 2019

Table 24: Anesthetic Effect – Pipeline by NutriBand Inc, H2 2019

Table 25: Anesthetic Effect – Pipeline by Paion AG, H2 2019

Table 26: Anesthetic Effect – Pipeline by Phosphagenics Ltd, H2 2019

Table 27: Anesthetic Effect – Pipeline by Physica Pharma, H2 2019

Table 28: Anesthetic Effect – Pipeline by Recro Pharma Inc, H2 2019

Table 29: Anesthetic Effect – Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H2 2019

Table 30: Anesthetic Effect – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019

Table 31: Anesthetic Effect – Pipeline by SiteOne Therapeutics Inc, H2 2019

Table 32: Anesthetic Effect – Pipeline by Sphaera Pharma Pte Ltd, H2 2019

Table 33: Anesthetic Effect – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H2 2019

Table 34: Anesthetic Effect – Dormant Projects, H2 2019

Table 35: Anesthetic Effect – Dormant Projects, H2 2019 (Contd..1), H2 2019

Table 36: Anesthetic Effect – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Anesthetic Effect, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Top 10 Targets, H2 2019

Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports